BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18158435)

  • 1. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.
    Wheeler A; Steingrub J; Schmidt GA; Sanchez P; Jacobi J; Linde-Zwirble W; Bates B; Qualy RL; Woodward B; Zeckel M
    Crit Care Med; 2008 Jan; 36(1):14-23. PubMed ID: 18158435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
    Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
    Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
    Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
    Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.
    Vincent JL; Nadel S; Kutsogiannis DJ; Gibney RT; Yan SB; Wyss VL; Bailey JE; Mitchell CL; Sarwat S; Shinall SM; Janes JM
    Crit Care; 2005 Aug; 9(4):R331-43. PubMed ID: 16137345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
    N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
    Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, observational study of Xigris Use in the United States (XEUS).
    Steingrub JS; Cheatham ML; Woodward B; Wang HT; Effron MB;
    J Crit Care; 2010 Dec; 25(4):660.e9-16. PubMed ID: 20435433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
    Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
    Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.
    Martin G; Brunkhorst FM; Janes JM; Reinhart K; Sundin DP; Garnett K; Beale R
    Crit Care; 2009; 13(3):R103. PubMed ID: 19566927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa (activated): real-life use and outcomes for the UK.
    Rowan KM; Welch CA; North E; Harrison DA
    Crit Care; 2008; 12(2):R58. PubMed ID: 18430215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
    Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
    Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
    Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
    Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.
    Vincent JL; O'Brien J; Wheeler A; Wittebole X; Garg R; Trzaskoma BL; Sundin DP
    Crit Care; 2006; 10(3):R74. PubMed ID: 16684364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
    Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
    Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
    Dhainaut JF; Yan SB; Joyce DE; Pettilä V; Basson B; Brandt JT; Sundin DP; Levi M
    J Thromb Haemost; 2004 Nov; 2(11):1924-33. PubMed ID: 15550023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.